[Treatment of obesity with the anoretic Sanorex].
Pathologically increased apetite is the most tormenting symptom of overweight conditions and therefore, along with dietetic treatment which plays an essential role, it is most expedient to resort to anorectic drugs also. Recently, the Sanorex preparation (Mazindol, Teronak, AN 448 degrees--imidazo-isoindole derivative having a tricyclic structure) is ever more extensively used. The action of the drug is studied in a series of 32 obesity individuals under sanatorial conditions and normocaloric diet, over a period of twenty seven days. The new preparation Sanorex which causes aversion to food, given in small doses, accounts for prompt and reliable control of the apetite--9590 kg reduction, 0,362 kg mean daily weight loss (p less than 0,05), and equal intensity of weight loss in either of the sexes (p less than 0,01). Side effects such as dryness in the mouth, very strong and moderate thurst, insomnia, superficial sleep, headache, elevated excitability, tachycardia, general feebleness are transitory, subside within two weeks, and are tolerated comparatively well by the patients included in the series. Sanorex administration may be recommended provided due consideration is given to the usual limitations implied by the continuous use of new drugs.
D000328:Adult; D001067:Appetite Depressants / Q000627:therapeutic use*; D001835:Body Weight / Q000187:drug effects; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000178:diet therapy / Q000188:drug therapy*; D013997:Time Factors
D001067:Appetite Depressants
Lechenie na zatlustiavaneto s anorektikuma sanoreks.